According to a TechSci Research report titled “Lung Cancer Therapeutics Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028″, the global market for lung cancer therapeutics is anticipated to experience substantial growth between 2024 and 2028. This growth is attributed to the availability of highly effective drugs, a surge in sedentary lifestyles, and an increasing need for customized therapy. Additionally, the market is being fueled by rising demand for personalized medicines and immunotherapy, as well as regulatory approvals of various drugs and treatments for lung cancer. However, the growth of the lung cancer therapeutics market is expected to be limited by the lack of effective treatment options, the widespread availability of generic drugs, and significant unmet demand for evaluation. Furthermore, radiotherapy and chemotherapy treatments carry a high risk of side effects, which is expected to impede market expansion. The lung cancer therapeutics market is segmented based on cancer cell type and treatment. The non-small cell lung cancer segment dominates the market due to its high prevalence globally and increasing diagnostic procedures, as well as investments by market players in non-small cell lung cancer research. The market is further divided into chemotherapy, radiation therapy, immunotherapy, targeted therapy, and other treatments, with the targeted therapy segment expected to hold the largest market share due to rising research and development efforts aimed at developing effective targeted therapeutics for lung cancer.
Browse over XX market data Figures spread through 110 Pages and an in-depth TOC on the “Global Lung Cancer Therapeutics Market.” – https://www.techsciresearch.com/report/lung-cancer-therapeutics-market/14700.html
Major companies operating in the global lung cancer therapeutics market are:
- AstraZeneca Plc
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- F. Hoffmann-La Roche AG.
- Merck & Co
- Pfizer Inc.
- Allergan Inc.
- Teva Pharmaceutical Industries Ltd.
- Abbvie, Inc.
- Johnson & Johnson
- Amgen Inc.
- Novartis AG
Recent Development
- The U.S. FDA approved Tagrisso as the initial therapy for non-small cell lung cancer with EGFR mutation in April 2018.
- Imfinzi’s approval was expanded by the U.S. FDA in February 2018 in an order to lower the risk of NSCLC’s progression.
Customers can also request for 10% free customization on this report.
North America currently holds the largest market share in the lung cancer therapeutics market, with growth in the region driven by the increased use of advanced lung cancer therapies and a rising incidence of lung cancer diagnosis. In addition to established cancer therapies like chemotherapy and targeted therapy, the adoption of advanced immunotherapies is also on the rise in developed nations, which is expected to contribute to market growth during the forecast period. Meanwhile, Europe is anticipated to be a potential growth segment for the lung cancer therapeutics market between 2024-2028. The market in this region is expected to grow due to increasing regulatory approvals and the adoption of advanced therapeutics. Additionally, emerging countries in the Asia Pacific, such as India, China, and Japan, are projected to fuel market growth due to the increasing prevalence of lung cancer in these countries, according to Mr. Karan Chechi, Research Director at TechSci Research, a global management consulting firm specializing in research-based analysis.
“Lung Cancer Therapeutics Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028, Segmented By Cancer Cell Type (Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), By Treatment (Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy, Other Treatments), and By Region,” has evaluated the future growth potential of global lung cancer therapeutics market and provides statistics & information on market size, structure, and future market growth. the report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in the global lung cancer therapeutics market.”
Related Reports:
Europe frontotemporal dementia market
China wearable medical devices market
China artificial organs market
About TechSci Research:
TechSci Research is a research-based management consulting firm providing market research and advisory solutions to its customers worldwide, spanning a range of industries. TechSci Research’s core values are value, integrity and insight. Led by a team of dynamic industry experts, TechSci Research provides its customers with high value market research and advisory services that helps them identify new market opportunities, growth engines and innovative ways to capture the market share. As a result, TechSci’s client leads rather than follow market trends. Not bound by legacy, TechSci’s cutting-edge research model leverages its decades of research knowledge and an increased use of technology as engines of innovation to deliver unique research value. Provided as an alternative to traditional market research, TechSci Research reports do not just deliver data and knowledge rather highlights the insights in a more usable and interactive format for its clients.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: sales@techsciresearch.com
Web: https://www.techsciresearch.com